You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. A daily client check-in system for outpatient substance abuse treatment

    SBC: COG ANALYTICS, LLC            Topic: NIDA

    Abstract Alcohol and illicit drug use remain highly prevalent in the US, and epidemiological surveillance surveys estimate that over 20.6 million individuals (~ 8% of the US population) meet standard diagnostic thresholds for substance use disorders (SAMHSA, 2011). Outpatient substance abuse treatment is the predominate method of treatment in the US for SUDs, typically involving intermittent cont ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Aminonaphthyridine compounds as potential therapeutics for lung and thyroid cancers

    SBC: KinaRx, LLC            Topic: 102

    Over the past three decades a growing number of cancer-driving protein kinases have been successfully targeted as reflected in the approval of 49 kinase inhibitors by the Food and Drug Administration (FDA). Recent approval of the first tyrosine kinase inhibitor (Larotrectinib) for treatment of any cancer bearing mutation in neurotrophic receptor kinase validated a novel paradigm of precision targe ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. An adjuvanted influenza vaccine platform for dose sparing, multiplexing, and rapid deployment

    SBC: POP Biotechnologies Inc.            Topic: NIAID

    Abstract Influenza is the cause of considerable morbidity and mortality globally. Certain groups, i.e., infants, pregnant young women, and older adults are especially at risk for severe disease. Despite immunization being the most effective and economical prophylactic approach, vaccines often provide less than optimal defense against an influenza illness, with efficacies ranging from 10-60%. This ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. A novel monobody-drug conjugate to treat mutant Ras multiple myeloma

    SBC: TEZCAT Laboratories LLC            Topic: 102

    Project Summary: Multiple myeloma is an incurable hematologic malignancy with an expected median survival of 7-8 years. The proteasome inhibitors, bortezomib, carfilzomib and the recently approved ixazomib, are a mainstay of current myeloma treatment. Despite an initial response rate approaching 90% to proteasome inhibitor-containing combinations, all patients relapse and eventually become resista ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. A Novel Strategy for Diagnosis of Esophageal Adenocarcinoma.

    SBC: CAPSULOMICS, LLC            Topic: 102

    Contact PD/PI: Abraham, John M Esophageal adenocarcinoma (EAC) is one of two major types of esophageal cancer, which causes 509,000 deaths worldwide annually. EAC diagnosis is made using the invasive, expensive, risky, and not universally accessible procedure, esophagogastroduodenoscopy (EGD). Thus, there is a pressing need for easier, safer, cheaper strategies for EAC diagnosis. Our novel strateg ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. A PET Diagnostic for Imaging Bacterial Infection

    SBC: CHRONUS PHARMACEUTICALS, INC.            Topic: NIBIB

    PROJECT SUMMARY Bacterial infections such as those of prosthetic joints, bones (osteomyelitis) and heart valves (infective endocarditis) are difficult to diagnose and treat, and are a major cause of mortality, morbidity and health care costs. The long-term goal of our program is to develop a positron emission tomography (PET) radiotracer that can be used for non-invasive PET imaging to detect and ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Clinical Translation of Augmented Reality Visualization for Laparoscopic Surgery

    SBC: IGI TECHNOLOGIES, INC            Topic: NCI

    DESCRIPTION (provided by applicant): The overall objective of the proposed research is to fully develop and conduct clinical translation of a novel technology that provides minimally invasive surgeons an ability to visualize exposed organ surfaces as wellas structures hidden by them, together with a true appreciation of depth. A long-standing need in minimally invasive laparoscopic surgery has bee ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. CNS Gene Therapy for CLN2 Disease Using Parallel Multiple Routes of Administration

    SBC: LEXEO Therapeutics LLC            Topic: NINDS

    Abstract. In partnership with the Crystal laboratory, Weill Cornell, LEXEO is developing an adeno-associ- ated virus (AAV)-based gene therapy to treat the central nervous system (CNS) manifestations of CLN2 (Batten) disease, a fatal, childhood autosomal recessive neurodegenerative lysosomal storage disorder caused by mutations in the CLN2 gene, coding for a lysosomal enzyme, tripeptidyl peptidase ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Determination of circulation factors that mediate the health benefits of exercise in mitochondrial aging

    SBC: CYTEGEN CORP            Topic: NIA

    Project Summary/Abstract: This proposal seeks to test the hypothesis that endurance exercise stimulates the release of circulating factors that improve mitochondrial fitness. CyteGen’s goal is to identify these endogenous factors and engineer them to treat diseases in which mitochondrial dysfunction is central. These diseases include neurodegenerative and other diseases associated with aging, as ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Developing a Nrf2 activator for the treatment of COPD

    SBC: CUREVEDA, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Chronic obstructive pulmonary disease (COPD) is a major cause of mortality and morbidity worldwide. In the US alone, the disease afflicts ~13 million people and is the third-leading cause of death. Cigarette smoking isthe primary risk factor for COPD, initiating a persistent and progressive inflammatory immune response. Respiratory infections and pollutants can ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government